Harrison

This research aims to evaluate the use of PET scans with two different radiotracers, FDG and FDHT, in men with progressive prostate cancer. The study focuses on whether these scans can better detect areas where the cancer may have spread in the body. It builds on earlier findings that changes in FDG uptake relate to cancer progression and treatment response, and now investigates FDHT, which targets the androgen receptor in prostate cancer. Participants will undergo PET scans using FDHT alone or both FDG and FDHT based on clinical questions. Scans will take place at baseline, 4 weeks, 12 weeks, and then every 12 weeks for up to one year, with a maximum of 8 scan sets per year and 40 over a lifetime unless otherwise directed. Some patients may have blood draws to study how FDHT moves through the body and may have an initial dynamic scan followed by a standard whole-body PET scan. During the study, researchers will assess where and how much FDHT accumulates in tumors, comparing these findings with other imaging like bone scans, CT, and MRI at baseline, 4 weeks, and 12 weeks. They will also monitor kinetics and metabolism of the tracer, changes over time, and correlations with disease markers and tissue analyses. The study involves repeated imaging and blood tests to better understand prostate cancer progression and response to treatment.

Researchers are evaluating whether a high-fiber plant-based diet (HFPBD) can improve quality of life for people with clonal hematopoiesis (CH). This diet mainly includes plant foods such as fruits, vegetables, nuts, beans, and whole grains. The study measures quality of life using questionnaires and surveys filled out by participants. Participants will be randomly assigned to one of two groups. One group will receive high-fiber plant-based meals delivered to their homes for 12 weeks and have regular phone or video calls with a dietitian every 2 weeks for the first 12 weeks, every 4 weeks from weeks 13 to 24, and every 8 weeks from weeks 25 to 52. The other group will receive usual care with phone calls every 4 weeks for the first 12 weeks and dietitian calls at weeks 13 and 53. During the study, participants will complete quality of life surveys using the EORTC QLQ C30 questionnaire. Assessments include phone or video visits with dietitians, dietary intake monitoring, and adherence to the assigned diet. The main outcome is improvement in quality of life within the first 12 weeks. The total study duration for participants is 52 weeks, with ongoing monitoring and support throughout this time.

Researchers are investigating whether a dietary intervention can influence treatment response and quality of life in people with newly diagnosed multiple myeloma undergoing standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The study aims to assess the effects of diet on quality of life, treatment response, and various disease, microbiome, and immune markers by having participants complete questionnaires and other evaluations. Participants are randomly assigned to one of two groups. One group receives usual care, which includes standard chemotherapy and phone calls every 4 weeks with study staff and a dietitian consultation at the end of chemotherapy. The other group receives an intervention with nutrition counseling and coaching, including biweekly dietitian calls for 12 weeks and high-fiber plant-based frozen meals shipped weekly for 12 weeks. Optional group sessions and text message reminders are also provided. Both groups complete dietary and quality of life surveys during the study. During the study, participants complete questionnaires measuring quality of life and dietary intake. Researchers will evaluate the rate of minimal residual disease negative complete response at one year and compare quality of life improvements between groups. Phone or video calls with dietitians and study staff support participant engagement. The study lasts through four 28-day chemotherapy cycles with follow-up assessments up to one year to monitor treatment and quality of life outcomes.

Researchers are evaluating whether telehealth music therapy can be a practical treatment for cognitive difficulties in adults who have survived blood cancers such as lymphoma, leukemia, or myeloma. The study also examines if music therapy and music education can help improve cognitive function as well as symptoms like anxiety, depression, and fatigue in this population. This pilot trial is exploring these effects in hematologic cancer survivors who experience cancer-related cognitive dysfunction. Participants will be assigned to one of three groups: the experimental music therapy (MT) group, the therapist-attention music education (TAME) control group, or a wait-list control (WLC) group receiving usual care. Those in the MT and TAME groups will receive 12 weekly 60-minute sessions, with homework assignments between sessions to reinforce skills and concepts. The WLC group completes assessments during a 24-week wait period and can later choose to receive either the MT or TAME intervention. During the study, participants will complete assessments to measure the feasibility of telehealth music therapy, defined by completing at least 9 of the 12 sessions. Researchers will monitor cognitive function, mood symptoms, and fatigue. Participants must be able to complete study assessments independently and consent in English. The total study duration includes the intervention period and follow-up assessments to evaluate outcomes related to cancer-related cognitive dysfunction.

This research focuses on people with primary lung cancer who are undergoing planned pulmonary segmentectomy, a surgical procedure to remove part of the lung. The study aims to collect real-world data on patients with clinical Stage I lung cancer, assessing their outcomes over time to better understand disease progression and recovery. The research is conducted by Memorial Sloan Kettering Cancer Center and involves an international registry to gather comprehensive information about this patient group. Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and again 6 months after surgery. The study collects patient-reported outcomes using the Patient-Reported Outcomes Measurement Information System (PROMIS), which evaluates physical function, pain interference, and shortness of breath. This setup helps researchers understand patients' experiences and recovery in a structured way. Throughout the study, researchers will track disease-free survival at both 3 years and 5 years after surgery to measure longer-term outcomes. Participants will provide information through surveys administered at scheduled times, and their health status will be monitored without affecting their usual medical care. The total participation duration extends over several years as outcomes are followed up to 5 years post-surgery to understand the effectiveness of pulmonary segmentectomy in real-world conditions.

Researchers are collecting detailed information in a registry to better understand various types of mature T-cell and natural killer (NK)-cell lymphomas. This observational study aims to improve knowledge about these rare blood cancers by creating a comprehensive database that includes clinical information and tumor samples from participants. The study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on multiple specific T-cell lymphoma subtypes as defined by recognized classification guidelines. Participants with confirmed mature T-cell or NK-cell lymphoma may choose to provide optional blood and nail samples for future research and biobanking. The study does not involve experimental treatments but gathers data prospectively from individuals meeting strict diagnostic criteria, including those receiving systemic therapy for certain cutaneous lymphoma types. This approach supports long-term data collection rather than testing new therapies. During the study, participants will have clinical data and tumor specimens collected and recorded. Researchers will track the number of participants contributing to the T-cell Lymphoma Master Repository over a 10-year period. The study involves ongoing follow-up to measure disease status and treatment response, with no direct intervention required. Participation helps build a resource to advance future research and understanding of these lymphomas.

Researchers are creating a registry to study people with early changes in the stomach lining that may lead to gastric cancer. This includes those with gastric atrophy, intestinal metaplasia, and dysplasia. The study also enrolls healthy individuals and people with gastric cancer to compare baseline characteristics and better understand risk factors for disease progression. Participants fall into three groups: those with specific stomach lesions, healthy controls, and people with gastric cancer. The study collects information through questionnaires about clinical history, environmental exposures, lifestyle, and diet. This observational study does not involve any treatment but gathers health data to support future research. Participants will complete questionnaires and provide health information over a period that may last up to 10 years. The main goal is to build a detailed participant registry. Researchers will monitor and analyze the collected data to identify factors related to the progression of stomach lesions to cancer. Participation involves regular data collection but no active treatment, with safety and privacy monitored throughout the study.

Researchers are studying how butyrate levels in stool change after following a plant-based diet for at least 12 weeks in people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). The study compares the effects of a plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo on these butyrate levels. This randomized, placebo-controlled trial is conducted by Memorial Sloan Kettering Cancer Center to explore nutritional interventions in these conditions. Participants will be assigned to one of three groups: a plant-based diet group receiving two premade meals daily for 12 weeks; a supplement group taking algae omega-3 and curcumin supplements twice daily for 52 weeks; or a placebo group receiving inactive supplements twice daily for 25 weeks. The plant-based diet includes low glycemic meals with legumes, vegetables, whole grains, and plant fats, coupled with dietary education and counseling every 4 weeks. During the study, participants will be monitored through stool samples to assess microbiome diversity at 12 weeks. They will receive ongoing dietary support and have access to study staff for questions. The study lasts up to 52 weeks depending on the group, with regular assessments to track adherence, safety, and changes in butyrate levels. The research aims to understand how diet and supplements affect gut health in MGUS and SMM patients.

Researchers are comparing two types of PET/CT scans to determine which is better at detecting and monitoring metastatic invasive lobular carcinoma (ILC), a type of breast cancer that is estrogen receptor positive (ER+). The study focuses on evaluating the use of fluorine 18 (18F)-fluoroestradiol (FES) PET/CT scans versus the standard 18F-fluorodeoxyglucose (FDG) PET/CT scans in people with metastatic ILC. The goal is to improve imaging methods for this specific breast cancer type, with support from Memorial Sloan Kettering Cancer Center. Participants will undergo FES PET/CT scans at the start of the study and again after treatment, within two weeks of their follow-up FDG PET/CT scans. Both types of scans will be compared to assess their effectiveness in detecting and monitoring metastatic disease. The study includes patients with biopsy-confirmed metastatic ER+ lobular breast cancer who meet specific health and treatment history criteria. During the study, participants will have both FES and FDG PET/CT scans at baseline and after treatment to monitor cancer status. Researchers will compare results from these imaging tests over a one-year period to evaluate which method provides better information about the cancer. Participants' health status, performance ability, and prior treatments are monitored to ensure safety. The study aims to gather important data to guide future imaging choices for metastatic lobular breast cancer.

Researchers are evaluating the effects of propranolol and etodolac combined with mind-body resilience training (MBRT) and music therapy on reducing physiological stress in women undergoing primary debulking surgery (PDS) or interval debulking surgery (IDS) for advanced ovarian, fallopian tube, or primary peritoneal carcinoma. The study compares these interventions to the standard care approach, which does not include specific stress-reduction treatments. This pilot randomized trial aims to understand if these combined interventions better manage stress during the perioperative period. Participants will be randomly assigned to one of two groups. The experimental group will receive MBRT, music therapy, propranolol (20 mg orally twice daily for 21 days, then 10 mg twice daily on postoperative days 14-16), and etodolac (400 mg orally twice daily for 21 days) before and after surgery. Postoperative psychological interventions may also be provided from postoperative days 1 to 7 if needed. The control group will receive usual care without these specific interventions. During the study, participants will be monitored for adherence to the interventions, with success defined as completing over 80% of the bundled treatments within 21 days after surgery. Researchers will evaluate stress reduction through psychological and physiological assessments during and after the surgical procedure. The study will continue until June 2026, with participant involvement including preoperative preparation, surgery, postoperative care, and follow-up assessments.